PMID- 18425299
OWN - NLM
STAT- MEDLINE
DCOM- 20080925
LR  - 20220330
IS  - 1471-4418 (Print)
IS  - 1475-1534 (Electronic)
IS  - 1471-4418 (Linking)
VI  - 17
IP  - 2
DP  - 2008 Jun
TI  - The use of omalizumab in asthma.
PG  - 62-72
LID - 10.3132/pcrj.2008.00031 [doi]
AB  - Asthma causes a substantial burden of morbidity and mortality, affecting 300 
      million people worldwide - a figure predicted to increase to 400 million by 2025. 
      Despite the availability of a variety of treatment options and detailed treatment 
      guidelines, many patients with asthma, and in particular those with severe 
      persistent asthma, remain inadequately controlled. Approximately 50-80% of severe 
      asthma has an allergic component, with immunoglobulin E (IgE) playing a role in 
      the underlying allergic inflammatory cascade. Omalizumab is a humanised 
      monoclonal anti-IgE antibody that targets IgE and partially inhibits the 
      inflammatory cascade. Clinical trials have demonstrated that omalizumab added to 
      standard asthma therapy reduces exacerbations and emergency visits with 
      concomitant improvements in asthma control and quality of life in patients with 
      moderate-to-severe and severe persistent allergic (IgE-mediated) asthma. Add-on 
      omalizumab is indicated for the treatment of patients with inadequately 
      controlled moderate-to-severe (US label) and severe (EU label) persistent 
      allergic asthma despite treatment with high-dose inhaled corticosteroids (and in 
      the EU, high-dose inhaled corticosteroids plus a long-acting beta2-agonist). 
      Within this highly-targeted patient population, analyses have been unable to 
      identify pre-treatment clinical characteristics that are predictive of a greater 
      response to omalizumab. In contrast, assessment of response to omalizumab 
      following 16 weeks of treatment appears to be reliably judged by physicians in 
      clinical trial settings and may be a feasible means of selecting patients who 
      should continue treatment.
FAU - Price, David
AU  - Price D
AD  - Department of General Practice and Priamary Care, University of Aberdeen, 
      Scotland, UK. david@respiratoryresearch.org
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Prim Care Respir J
JT  - Primary care respiratory journal : journal of the General Practice Airways Group
JID - 101121543
RN  - 0 (Adrenergic beta-2 Receptor Agonists)
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Leukotriene Antagonists)
RN  - 0 (Receptors, Adrenergic, beta-2)
RN  - 2P471X1Z11 (Omalizumab)
SB  - IM
MH  - Adrenergic beta-2 Receptor Agonists
MH  - Anti-Asthmatic Agents/administration & dosage/*therapeutic use
MH  - Antibodies, Anti-Idiotypic
MH  - Antibodies, Monoclonal/administration & dosage/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Asthma/complications/*drug therapy
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Leukotriene Antagonists/administration & dosage
MH  - Omalizumab
MH  - Receptors, Adrenergic, beta-2/administration & dosage
PMC - PMC6619882
COIS- DP has no shares in pharmaceutical companies. He has received speaker's honoraria 
      for speaking at sponsored meetings from the following companies marketing 
      respiratory products: 3M, Altana, Astra Zeneca, BI, GSK, IVAX, MSD, Novartis, 
      Pfizer, Schering-Plough. He has received honoraria for advisory panels with; 3M, 
      Altana, Astra Zeneca, BI, GSK, IVAX, MSD, Novartis, Pfizer, Schering-Plough. He 
      or his research team have received funding for research projects from: 3M, 
      Altana, Astra Zeneca, BI, GSK, IVAX, MSD, Novartis, Pfizer, Schering-Plough, 
      Viatris.
EDAT- 2008/04/22 09:00
MHDA- 2008/09/26 09:00
PMCR- 2008/06/01
CRDT- 2008/04/22 09:00
PHST- 2008/04/22 09:00 [pubmed]
PHST- 2008/09/26 09:00 [medline]
PHST- 2008/04/22 09:00 [entrez]
PHST- 2008/06/01 00:00 [pmc-release]
AID - SG00108 [pii]
AID - 10.3132/pcrj.2008.00031 [doi]
PST - ppublish
SO  - Prim Care Respir J. 2008 Jun;17(2):62-72. doi: 10.3132/pcrj.2008.00031.